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1. Introduction 
Increasing interest in the physiological role of the 
various prostaglandins (Pgs) has lead to the develop- 
ment of specific radioimmunoassays for many of 
these compounds [1-6]. However, it is well known 
that prostaglandins, especially of the E and F type, 
are rapidly inactivated by many tissues [7,8]. There- 
fore, the determination f Pg metabolites might of- 
ten add valuable information as to total Pg release by 
a tissue. The first steps of enzymatic nactivation are 
generally oxidation of the C1 s hydroxyl group to 
form 15-keto-prostaglandins and then reduction of 
the C13-C~ 4 double bond. Radioimmunoassays for 
15-keto-PgF2 e and 13,14-dihydro- 15-keto-PgF2 o 
have been described recently [9-13]. 13,14-Dihydro- 
15-keto-PgE2 was measured only indirectly so far, 
making use of its cross-reaction with an antiserum 
against 13,14-dihydro-15-keto-PgF2 t~ [ 14]. While 
96% of the serologic activity of 13,14-dihydro-15-keto- 
PgE2 was destroyed by heating at 100°C at pH 
12.5 for 5 rain, 13,14-dihydro- 15-keto-PgF2 a was 
stable under such conditions. Radioimmunoassay be- 
fore and after heating at alkaline pH gave an indirect 
estimate of the amount of the PgE2-metabolite. This 
paper describes the production of specific antisera 
against 13,14-dihydro- 15-keto-PgE2 and their use for 
radioimmunoassay. 
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2. Materials and methods 
The prostaglandins El, E2, Fl,~, F~ a, A1, As and 
the metabolites 13,14-dihydro-15-keto-PgE2, 15-keto- 
PgE2, 13,14-dihydro-15-keto-PgF2 c~ and 15-keto-Pgf2 
were generous gifts of Dr. J. Pike (Upjohn Co. Kalama- 
zoo, USA). PgBI and PgB2 were prepared according 
to the method of Zusman [15] from PgE1 and PgE2 
respectively. PgE2-5,6,8,11,12,14,15-H 3 (specific ac- 
tivity 125 Ci/mmol) was bought from New England 
Nuclear.Co. The antigen for immunization of the 
rabbits was synthetized by the method of Goodfriend 
et al. [16], using 7.5 mg bovine serum albumin (BSA), 
4 mg 1-ethyl-3-(3-dimethyl-aminopropyl)-carbodii- 
mide and 3 mg 13,14-dihydro-15-keto-PgEz. After 
incubation at room temperature overnight the prepa- 
ration was dialyzed exhaustively against many chan- 
ges of distilled water. 100/ag of antigen in 0.5 ml 
saline were emulsified with an equal volume of com- 
plete Freund's adjuvant and injected into the toe pads 
of rabbits, followed by 100/ag one week later and 
then at monthly intervals. The rabbits were bled 
10-14 days after booster injections. Microcomple- 
ment f'Lxation was performed as described by Levine 
[171. 
The radioactive antigen was prepared from 3 H-PgE2 
as described by Anggard et al. [18], using guinea pig 
lung as enzyme source. Briefly, lungs of guinea pigs 
were rapidly excised and transferred toice-cold 
Bucher medium (0.02 M KH~PO4, 0.072 M K2HPO4, 
0.0276 M nicotinamide, 0.0036 M MgCI2, pH 7.4) 
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to which 1/~g/ml indomethacin had been added. Indo- 
methacin was added to prevent synthesis of endoge- 
nous Pgs during the following procedures. The lungs 
were minced and homogenized in an Ultra-Turrax ho- 
mogenizer (Janke and Kunkel, KG, Staufen, Germa- 
ny). After centrifugation at900 g for 15 rain, the 
supernatant was centrifuged at 105 000 g for 60 rain. 
Ten ~tl 0.01 M NAD and 250 nmCi H a-PgE2 were 
added to portions of 1 ml of supernatant. The mix- 
tures were incubated at 37°C for 1 hr. Incubation 
was stopped by the addition of 5 ml absolute thanol. 
Five ml H20 were then added and the mixtures aci- 
dified to pH 3.0 with N HC1. They were then extrac- 
ted with 20 ml ether. After centrifugation the organic 
phase was taken off and evaporated in a stream of 
air. The residues containing more than 80% of the ori- 
ginal radioactivity were dissolved in 70% ethanol. 
According to Angg~rd et al. [18] this procedure re- 
suits in the formation of two PgE2 metabolites, 13, 
14-dihydro-15-keto-PgE2 and 13,14-dihydro-PgE2. 
No attempt was made to separate these two com- 
pounds. 
Radioimmunoassay was performed as described 
previously [6], using 0.5 ml charcoal suspension (20 
mg/ml) for separation of bound and free fractions. 
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Fig. 1. Complement fixation of rabbit anti-13,14-dihydro- 
15-keto-PgE 2 at 1:600 dilution with 13,14-dihydxo-15-keto- 
PgE2-carbodiimide-BSA (×') Or BSA (o). 
3. Results and discussion 
All three rabbits immunized with the 13,14-dihy- 
dro- 15-keto-PgE2-conjugate developed specific anti- 
bodies within a few weeks. The presence of antibo- 
dies in the sera was checked for by microcomple- 
ment fLxation. The complement fixation obtained 
using the antiserum at a 1:600 dilution and the 13, 
14-dihydro-15-keto-PgE2-carbodiimide-BSA conju- 
gate or BSA alone as the antigen is shown in fig. 1. 
While up to 80% of the complement were fLxed in 
the presence of the specific antigen at this antiserum 
dilution, there was minimal fixation using the carrier 
protein BSA as antigen. The specificity of the fixa- 
tion is further shown by inhibition experiments a
illustrated in fig. 2. 13,14-dihydro-15-keto-PgE2 i~ a 
better inhibitor in the complement fLxation system 
than 15-keto-PgE2. PgE2 in amounts up to 10/ag 
does not inhibit the reaction at all. 
The specificity of the radioimmunoassay, using 
H a-PgE2 that had been incubated with guinea pig 
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Fig. 2. Inhibition of complement fLxation by 13,14-dihydro+ 
15-keto-PgE 2 (X), 15-keto-PgE 2 (A) and PgE~ (o). The 
antiserum dilution was 1:600 and 0.55 ug Of the antigen 
was used. 
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Table 1 
Ptostaglandin Nanograms required Relative cross- 
to displace 50% ~eaction (%) 
of bound label 
13,14-dihydro-15- 
keto-PgE 2 3.6 100 
PgA~ 80.2 4.5 
15-keto-PgE 2 101.4 3.6 
PgA 1 227.4 1.6 
13,14-dihydro-15- 
keto-PgF 2a 689.5 0.5 
15-keto-PgF2 a > 1000.0 < 0.4 
PgE 1 > 1000.0 < 0.4 
PgE 2 > 1000.0 < 0.4 
PgB~ > 1000.0 < 0.4 
PgB2 > 1000.0 < 0.4 
PgFI a > 1000.0 < 0.4 
PgF2a > 1000.0 < 0.4 
Specificity of antiserum against 13,14-dihydro- 15-keto-PgE~ 
as measured by radioimmunoassay. The final antiserum dilu- 
tion was 1:1200 and 4000 epm/tube of labelled antigen 
1~lre used. 
lung homogenate as the labelled antigen, is shown in 
table 1. The antiserum was used at a 1:1200 final dilu- 
tion in these experiments. This antiserum dilution 
bound about 40% of the added radioactivity (4000 
cpm). The best inhibitor in this system is 13,14-dihy- 
dro.15-keto-PgE2, 3.6 ng producing 50% inhibition 
of binding of labelled antigen to the antiserum. The 
assay is linear from 400 pg up to 40 ng for this com- 
pound. 15-Keto-PgE2, differing only by the presence 
of the C1 a-C~ a double bond, shows 3.6% relative 
cross-reaction and PgE2 less than 0.4%. These results 
indicate the immunodominance of the 15-keto group 
and the reduced C~ 3-C~ 4 double bond in the antigen 
molecule. This observation is further supported by 
the fact, that 13,14-dihydro- 15-ke to.PgF ~ a, having 
the same side chains as 13,14-dihydro-15-keto-PgE2 
but a different ring structure, was recognized by the 
antiserum to some extent, while 15-keto-PgF2~, and 
PgF2 ~, did not interfere with the assay. 13,14-Dihy- 
dro-PgE2 was not available to us, but some cross- 
reaction by this compound can be expected from the 
above results. An antiserum against 13,14-dihydro- 
15-keto-PgF2 a showed a relative cross-reaction of
2.5% with the corresponding 13,14-dihydro-PgF2 
[9]. 
While Pgs of the E, F and B series bind only negli- 
gibly to the antiserum against 13,14-dihydro- 15-keto- 
PgE2, PgA2 and PgA1 were found to cross-react 
significantly. Similarly, immunization with PgEI - 
and PgE2-conjugates has lead to the production of 
antisera, which bind best PgA1 and PgA2 respective- 
ly [1,4]. Obviously the PgE ring structure in the im- 
munogen can easily be dehydrated either chemically 
during the coupling procedure or enzymatically [19], 
thereby being transformed into the PgA ring structure. 
Cornette t al. [12] pointed out the advantages of a 
radioimmunoassay for 13,14-dihydro- 15-keto-PgF2 a, 
the biologically inactive PgF2 a metabolite. Similarly, 
13,14-dihydro-15-keto-PgE2 is a biologically inactive 
metabolite of PgE2, which cannot be determined by 
bioassay. The radioimmunoassay described here, 
being sufficiently specific, is presently being used for 
the measurement of this compound in biological 
material. 
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